Shedding New Light on the Magnitude of Thrombosis Risk in Patients With Myeloproliferative Neoplasms
Authors: Alison R. Moliterno, Elizabeth V. Ratchford
Journal: Annals of Internal Medicine (2018)

Editorials6 March 2018Shedding New Light on the Magnitude of Thrombosis Risk in Patients With Myeloproliferative NeoplasmsAlison R. Moliterno, MD and Elizabeth V. Ratchford, MDAlison R. Moliterno, MDJohns Hopkins University School of Medicine, Baltimore, Maryland (A.R.M., E.V.R.)Search for more papers by this author and Elizabeth V. Ratchford, MDJohns Hopkins University School of Medicine, Baltimore, Maryland (A.R.M., E.V.R.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-3153 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Myeloproliferative diseases were first described by William Dameshek in 1951. In 2008, the World Health Organization established a new classification system and introduced the term “myeloproliferative neoplasms” (MPNs). Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are the most prevalent MPNs and are characterized by overproduction of leukocytes, erythrocytes, or platelets; development of bone marrow fibrosis; leukemic transformation; and arterial and venous thrombosis. When Dameshek proposed the term “myeloproliferative diseases,” he also proposed the presence of a then-undiscovered stimulus that drove proliferation. We now understand that mutation of the JAK2 gene, JAK2 V617F, is the most common stimulus, ...References1. Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, et al. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015;13:424-34. [PMID: 25870379] CrossrefMedlineGoogle Scholar2. Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms. A population-based cohort study. Ann Intern Med. 2018;168:317-25. doi:10.7326/M17-0028 LinkGoogle Scholar3. Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica. 2014;99:1448-55. [PMID: 24907356] doi:10.3324/haematol.2014.107631 CrossrefMedlineGoogle Scholar4. Hinds DA, Barnholt KE, Mesa RA, Kiefer AK, Do CB, Eriksson N, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood. 2016;128:1121-8. [PMID: 27365426] doi:10.1182/blood-2015-06-652941 CrossrefMedlineGoogle Scholar5. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488-98. [PMID: 25426837] doi:10.1056/NEJMoa1408617 CrossrefMedlineGoogle Scholar6. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219-25. [PMID: 22318201] doi:10.1182/blood-2011-11-394775 CrossrefMedlineGoogle Scholar7. Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep. 2013;15:295. [PMID: 23225175] doi:10.1007/s11883-012-0295-3 CrossrefMedlineGoogle Scholar8. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-1131. [PMID: 28845751] doi:10.1056/NEJMoa1707914 CrossrefMedlineGoogle Scholar9. Cavallari I, Morrow DA, Creager MA, Olin J, Bhatt DL, Steg PG, et al. Frequency, predictors and impact of combined antiplatelet therapy on venous thromboembolism in patients with symptomatic atherosclerosis. Circulation. 2017. [PMID: 29084737] doi:10.1161/CIRCULATIONAHA.117.031062 CrossrefMedlineGoogle Scholar10. Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN Guidelines insights: myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw. 2017;15:1193-1207. [PMID: 28982745] doi:10.6004/jnccn.2017.0157 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Johns Hopkins University School of Medicine, Baltimore, Maryland (A.R.M., E.V.R.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-3153.Corresponding Author: Alison R. Moliterno, MD, Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Ross Research 1025, 720 Rutland Avenue, Baltimore, MD 21205; e-mail, [email protected]edu.Current Author Addresses: Dr. Moliterno: Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Ross Research 1025, 720 Rutland Avenue, Baltimore, MD 21205.Dr. Ratchford: Johns Hopkins Center for Vascular Medicine, Johns Hopkins University School of Medicine, 10755 Falls Road, Suite 360, Lutherville, MD 21093.This article was published at Annals.org on 16 January 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRisk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms Malin Hultcrantz , Magnus Björkholm , Paul W. Dickman , Ola Landgren , Åsa R. Derolf , Sigurdur Y. Kristinsson , and Therese M.L. Andersson Metrics Cited byRecurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasmsUnmasking and aggravation of polycythemia vera by canagliflozin 6 March 2018Volume 168, Issue 5Page: 363-364KeywordsCardiovascular disease riskGenomicsHazard ratioHigh sensitivity c reactive proteinInflammationLongitudinal studiesMedical risk factorsPrecision medicineThrombosisVascular medicine ePublished: 16 January 2018 Issue Published: 6 March 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...